EVE Health Group Limited Total Assets
EVE Health Group Limited total assets. Based on the latest financial reports, EVE Health Group Limited (EVE) holds total assets worth AU$4.07 Million AUD (≈ $2.88 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see EVE Health Group Limited (EVE) total market value for the company's overall valuation and market capitalisation.
Total Assets of EVE Health Group Limited (2004–2025)
Total assets of EVE Health Group Limited from 2004 to 2025. This chart illustrates how EVE Health Group Limited's total assets have evolved over time, based on quarterly financial data. See EVE stock price for real-time trading data and today's change.
EVE Health Group Limited - Asset Composition Analysis
EVE Health Group Limited Total Assets Breakdown (June 2025)
EVE Health Group Limited total assets breakdown as of June 2025. EVE Health Group Limited's total assets of AU$4.07 Million consist of 27.4% current assets and 72.6% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$903.42K | 21.9% |
| Accounts Receivable | AU$42.27K | 1.0% |
| Inventory | AU$183.96K | 4.5% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$3.00 Million | 72.6% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how EVE Health Group Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore EVE net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: EVE Health Group Limited's current assets represent 27.4% of total assets in 2025, an increase from 15.0% in 2004.
- Cash Position: Cash and equivalents constituted 21.9% of total assets in 2025, up from 10.6% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 72.6% of total assets.
EVE Health Group Limited Competitors by Total Assets
Key competitors of EVE Health Group Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
The a2 Milk Company Ltd
AU:A2M
|
Australia | AU$1.96 Billion |
|
Lotus Health Group Co
SHG:600186
|
China | CN¥3.86 Billion |
|
Cisarua Mountain Dairy Tbk PT
JK:CMRY
|
Indonesia | Rp9.48 Trillion |
|
Xiamen Kingdomway Group Co
SHE:002626
|
China | CN¥8.38 Billion |
|
Aryzta AG
SW:ARYN
|
Switzerland | CHF1.89 Billion |
|
Jiangsu Hengshun Vinegar-Industry Co Ltd
SHG:600305
|
China | CN¥4.24 Billion |
|
Yan Tai Shuang Ta Food Co Ltd
SHE:002481
|
China | CN¥4.48 Billion |
|
SDIC Zhonglu Fruit Juice Co Ltd
SHG:600962
|
China | CN¥2.23 Billion |
EVE Health Group Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.48 | 1.85 | 10.95 |
| Quick Ratio | 3.15 | 1.44 | 9.24 |
| Cash Ratio | 3.02 | 0.79 | 8.53 |
| Working Capital | AU$762.50K | AU$417.11K | AU$5.80 Million |
EVE Health Group Limited - Advanced Valuation Insights
This section examines the relationship between EVE Health Group Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.60 |
| Latest Market Cap to Assets Ratio | 0.72 |
| Asset Growth Rate (YoY) | 63.5% |
| Total Assets | AU$4.12 Million |
| Market Capitalization | $2.97 Million USD |
Valuation Analysis
Below Book Valuation: The market values EVE Health Group Limited's assets below their book value (0.72x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: EVE Health Group Limited's assets grew by 63.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for EVE Health Group Limited (2004–2025)
The table below shows the annual total assets of EVE Health Group Limited from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$4.12 Million ≈ $2.92 Million |
+63.49% |
| 2024-06-30 | AU$2.52 Million ≈ $1.79 Million |
-38.97% |
| 2023-06-30 | AU$4.13 Million ≈ $2.93 Million |
-48.79% |
| 2022-06-30 | AU$8.07 Million ≈ $5.71 Million |
-32.30% |
| 2021-06-30 | AU$11.92 Million ≈ $8.44 Million |
-15.51% |
| 2020-06-30 | AU$14.11 Million ≈ $9.99 Million |
+60.77% |
| 2019-06-30 | AU$8.78 Million ≈ $6.21 Million |
+17.72% |
| 2018-06-30 | AU$7.46 Million ≈ $5.28 Million |
+142.81% |
| 2017-06-30 | AU$3.07 Million ≈ $2.17 Million |
+59.74% |
| 2016-06-30 | AU$1.92 Million ≈ $1.36 Million |
-30.67% |
| 2015-06-30 | AU$2.77 Million ≈ $1.96 Million |
-66.14% |
| 2014-06-30 | AU$8.19 Million ≈ $5.79 Million |
-0.82% |
| 2013-06-30 | AU$8.26 Million ≈ $5.84 Million |
-65.13% |
| 2012-06-30 | AU$23.68 Million ≈ $16.76 Million |
-11.23% |
| 2011-06-30 | AU$26.68 Million ≈ $18.88 Million |
+1.13% |
| 2010-06-30 | AU$26.38 Million ≈ $18.67 Million |
+13.06% |
| 2009-06-30 | AU$23.33 Million ≈ $16.51 Million |
-13.04% |
| 2008-06-30 | AU$26.83 Million ≈ $18.98 Million |
+38.14% |
| 2007-06-30 | AU$19.42 Million ≈ $13.74 Million |
+208.44% |
| 2006-06-30 | AU$6.30 Million ≈ $4.46 Million |
+152.24% |
| 2005-06-30 | AU$2.50 Million ≈ $1.77 Million |
+531.49% |
| 2004-06-30 | AU$395.33K ≈ $279.72K |
-- |
About EVE Health Group Limited
EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erect… Read more